Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ACG 801

Next Previous
Drug Profile

ACG 801

Alternative Names: ACG-801; Recombinant human acid ceramidase- Sumitomo Pharma America; RVT-801

Latest Information Update: 18 Jul 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Icahn School of Medicine at Mount Sinai
  • Developer Aceragen
  • Class Ceramidases
  • Mechanism of Action Acid ceramidase replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Farber lipogranulomatosis
  • New Molecular Entity No

Highest Development Phases

  • Phase III Farber lipogranulomatosis
  • Preclinical Cystic fibrosis

Most Recent Events

  • 13 Apr 2023 Aceragen has patent protection for certain compositions, method of making and methods of use with respect to acid ceramidase and ACG 801 in USA, Europe, Japan, Israel, Mexico, and Hong-Kong
  • 13 Apr 2023 Aceragen has patent protection for claims related to certain methods of treating infections in patients with cystic fibrosis, chronic obstructive pulmonary disease, or an open wound using acid ceramidase and ACG 801 in USA, Europe, Hong-Kong, and Japan
  • 13 Apr 2023 Aceragen has patents pending for certain compositions, method of making and methods of use with respect to acid ceramidase and ACG 801 in Brazil, Canada, Europe, Hong-Kong, Japan, Israel, Mexico, Saudi Arabia, and USA
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top